Sep 2026· Journal of Neuroimmunology· Vol 421, pp.
579094
· 0 citations· 21 references
Medicine
TL;DR
A retrospective observational case series expands upon limited related literature and explores potential gut-brain immune associations in a subset of patients with AE and explores potential gut-brain immune associations in a subset of patients with AE.
Abstract
Objective
To report coexistence of autoimmune encephalitis (AE) and gastrointestinal inflammatory pathology, including malignancy.
Methods
We performed a retrospective observational case series of patients seen at Massachusetts General Brigham and University of Pittsburgh Medical Center during routine clinical care for AE, who had coexisting gastrointestinal inflammatory pathology. Clinical, paraclinical, treatment, and outcome data were reviewed.
Results
Sixteen patients (44% female, median age 64 years) with AE and gastrointestinal inflammatory pathology were identified. Presenting neurologic features included cognitive dysfunction (50%), seizures (44%), and psychiatric symptoms (44%). Clinically congruent neural autoantibodies were identified in 9/16 patients (56%) (GFAP, n = 3; LGI1, n = 3; GAD65, n = 1; PCA-1, n = 1; PCA-2, n = 1). Brain MRI abnormalities were present in 8/16 (50%), CSF pleocytosis in 6/16 (38%), elevated CSF protein in 7/16 (44%), CSF-unique oligoclonal bands in 3/10 tested (30%), and matched bands in 6/10 tested (60%). Gastrointestinal pathology included gastrointestinal tumor in 5/16 (31%) and inflammatory bowel disease in 4/16 (25%). AE followed gastrointestinal disease in 7/16 patients (44%), was diagnosed concurrently in 7/16 (44%), and preceded gastrointestinal disease in 2/16 (12%). Gastrointestinal symptoms or imaging findings were present at the onset of neurologic symptoms in 81% of patients. Fifteen of 16 patients (94%) received immunotherapy, and 12/16 (75%) had a modified Rankin Scale score of 0-2 at last follow-up. All deaths (3/16; 19%) occurred in patients with metastatic gastrointestinal malignancy.
Conclusions
This case series expands upon limited related literature and explores potential gut-brain immune associations in a subset of patients with AE.
To explore the clinical characteristics of atezolizumab-associated encephalitis and to provide clinical evidence for diagnosis and treatment.
Clinical reports on atezolizumab-associated encephalitis published before June 30, 2026 were collected for retrospective analysis by searching Chinese and English data...
Chun-Jiang Wang, Wei Sun, Li-Ping Peng et al.· Frontiers in Immunology· 0 citations
Celiac disease (CD) is an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals, leading to small intestinal damage and malabsorption. While gastrointestinal symptoms like diarrhoea are commonly associated with CD, more than 50% of adults with the condition experience significant extr...
Anti-leucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis is a rare neurological disorder caused by autoantibodies targeting the LGI1 protein, leading to synaptic dysfunction predominantly affecting the temporal lobes and hippocampi. It is mainly characterized by cognitive impairment, focal seizures, and fa...
L. Wolff, Mathieu Zuber, V. Roubeau· La Revue de medecine interne· 0 citations
First-line immunotherapy (steroids, IVIg), with escalation to rituximab in resistant cases, and anti-NMDAR antibody-positive AE with features of Kluver-Bucy syndrome are reported.
N. Manoj Kumar, A. Kumar, Vignesh Anbalagan et al.· Neurology India· 0 citations
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune inflammatory demyelinating disorder of the central nervous system with a broad clinical spectrum that includes brainstem syndromes. Evidence supporting neonatal Fc receptor (FcRn) inhibition in MOGAD remains limited.
A 3...
Fang-Shu Liu, Si-Yao Li, Mi-Duo Tan et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.